Hikma Pharmaceuticals (HKMPF)
(Delayed Data from OTC)
$25.70 USD
0.00 (0.00%)
Updated Sep 13, 2024 02:56 PM ET
2-Buy of 5 2
A Value A Growth D Momentum A VGM
Company Summary
Hikma Pharmaceuticals PLC develops, manufactures and markets pharmaceutical products. Its brand portfolio includes branded, injectables and generic. Branded segment offers dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system, oncology and respiratory. Injectables segment offers dosage for CNS, controlled substances, anti-infective, cardiovascular and oncology in form of liquid, semi-liquid and powdered form. Generics segment offers dosage for therapeutic including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory and hormonal. Hikma Pharmaceuticals PLC is based in London, the United Kingdom.
Company Summary
General Information
Hikma Pharmaceuticals Plc
1 New Burlington Place
London, X0 W1S 2HR
Phone: 44-20-7399-2760
Fax: 44-0-20-7399-2761
Web: http://www.hikma.com
Email: investors@hikma.uk.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | NA |
EPS Information
Current Quarter EPS Consensus Estimate | NA |
Current Year EPS Consensus Estimate | 2.22 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | NA |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 25.70 |
52 Week High | 26.50 |
52 Week Low | 21.28 |
Beta | 0.61 |
20 Day Moving Average | 127.65 |
Target Price Consensus | 0.00 |
4 Week | -0.54 |
12 Week | 1.78 |
YTD | 12.79 |
4 Week | -0.50 |
12 Week | -0.76 |
YTD | -4.24 |
Shares Outstanding (millions) | 220.23 |
Market Capitalization (millions) | 5,659.88 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 2.49% |
Annual Dividend | $0.64 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | 8/16/2024 / $0.32 |
Fundamental Ratios
P/E (F1) | 11.58 |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | NA |
vs. Previous Quarter | NA |
vs. Previous Year | NA% |
vs. Previous Quarter | NA% |
Price/Book | 2.56 |
Price/Cash Flow | 7.72 |
Price / Sales | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 1.57 |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 0.90 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 9.77 |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 10.03 |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 1.70 |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 0.47 |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 31.80 |